Biosergen AS is a biotechnology company focused on developing new antifungal drugs aimed at treating severe invasive fungal infections. The company was founded to commercialize research and inventions from SINTEF and the University of Science and Technology in Trondheim, Norway. Biosergen's flagship product, BSG005, is a potentially groundbreaking antifungal drug that has shown significant safety and efficacy advantages over existing treatments. The company operates in the biopharmaceutical sector and primarily serves healthcare providers and patients dealing with severe fungal infections like Candida and Aspergillus. Biosergen's business model revolves around the research, development, and commercialization of its antifungal drugs. Revenue is generated through the sale of these drugs, licensing agreements, and potential partnerships with larger pharmaceutical companies. The company is currently in the clinical development phase, working to bring BSG005 to market as a first-line defense against life-threatening fungal infections.

Keywords: antifungal, BSG005, invasive fungal infections, biotechnology, SINTEF, Trondheim, Candida, Aspergillus, clinical development, biopharmaceutical.